Regulator will issue a fresh show-cause notice to Cipla before taking a new decision on the Pune facility
JAIPUR: Cipla has got temporary relief in a regulatory dispute after the Maharashtra Food and Drug Administration (FDA) agreed to withdraw its order cancelling the drug-sale licence of the company’s Carrying and Forwarding (C&F) facility at Wadki in Pune.
The development followed proceedings before the Bombay High Court, where the court questioned the manner in which the FDA had handled the matter. The court criticised the regulator for going “overboard” and raised concerns over whether Cipla had been given a proper opportunity to present its case.
Following the court proceedings, the FDA agreed to withdraw the cancellation order with immediate effect.
The regulator will now issue a fresh show-cause notice to Cipla. The company will be allowed to respond to the allegations, after which the FDA will take a fresh decision and issue a reasoned order.
For Cipla, the withdrawal removes the immediate impact of the licence cancellation. However, the regulatory matter itself is not over.
What Led to the Licence Cancellation?
The dispute relates to inspections carried out at Cipla’s Wadki facility in Pune and the handling of Reactin Plus Tablets, a Schedule H prescription medicine.
The Maharashtra FDA had raised several concerns following its inspection. These included issues related to product packaging, storage, stock records and compliance with a product recall.
One of the main objections concerned the words “Analgesic & Antipyretic” printed on the packaging of Reactin Plus.
The regulator considered the wording unauthorised for the prescription medicine and treated it as a violation of applicable drug regulations.
The FDA also seized Reactin Plus stock valued at around ₹11.19 lakh and directed that the affected stock be withdrawn from the market.
Further observations relating to storage and documentation were also cited by the regulator.
Based on these findings, the FDA ordered the cancellation of the drug-sale licences of the Pune C&F facility, with the cancellation taking effect from August 27, 2026.
Why Did Cipla Approach the High Court?
Cipla challenged the FDA's decision before the Bombay High Court.
The company argued that the order did not raise any concerns about the safety, quality or efficacy of its products. Cipla also questioned the procedure followed by the regulator before cancelling the licence.
A major point of contention was the hearing offered to the company.
According to Cipla's submissions before the court, the FDA had asked the company to appear for a hearing on August 26. The date was a public holiday, and Cipla sought an adjournment because a representative was not available.
The company said the FDA nevertheless proceeded with the cancellation order.
The issue drew the court's attention.
The Bombay High Court questioned the decision to call the company for a hearing on a public holiday and then proceed with the cancellation after the company sought more time.
The court also expressed concerns about the principles of natural justice and the manner in which the regulatory proceedings had been conducted.
FDA Withdraws the Cancellation Order
Following the court proceedings, the Maharashtra FDA agreed to withdraw the cancellation order.
This means the earlier licence cancellation will no longer remain in force.
But the regulator has not closed the case.
Instead, the FDA will start the process again by issuing a fresh show-cause notice to Cipla.
The company will have an opportunity to respond to the allegations and present its position. The FDA will then consider the response before passing a fresh, reasoned order.
That distinction matters.
The latest development should not be interpreted as a clean regulatory chit for Cipla. The allegations raised during the inspection remain part of the regulatory process and could still be examined by the FDA.
What has changed is the procedure through which the regulator will now consider the matter.
What It Means for Cipla
For investors, the immediate development is broadly positive.
The withdrawal of the cancellation order removes the immediate uncertainty surrounding the drug-sale licence of the Pune C&F facility. It also gives Cipla another opportunity to defend its position before the regulator.
At the same time, the final outcome remains uncertain.
The fresh show-cause notice and the FDA's eventual order will be the key events to watch. Depending on the regulator's findings and Cipla's response, the matter could end without further major action or could result in another regulatory order.
Investors should therefore distinguish between withdrawal of the earlier order and closure of the regulatory case. They are not the same thing.
The issue is also linked to the specific Pune C&F facility and the regulatory concerns surrounding Reactin Plus. It should not automatically be viewed as a regulatory action against Cipla's entire business or product portfolio.
What Happens Next?
The next stage will begin with the FDA issuing its fresh show-cause notice.
Cipla will then have an opportunity to respond to the allegations and provide its explanation.
After considering the company's response, the regulator is expected to pass a fresh and reasoned order.
For the market, that final order will be more important than the withdrawal of the earlier cancellation order because it will determine whether any regulatory action remains against the Pune facility.
Until then, the matter remains open.
Aurelius Business View
The FDA's decision to withdraw the licence cancellation is a near-term positive for Cipla, particularly because it removes the immediate regulatory action against the Pune C&F facility.
However, investors should not treat the development as the end of the dispute.
The Bombay High Court's intervention has primarily put the focus on the procedure followed by the FDA. The regulator will now have to restart the process and consider Cipla's response before reaching a fresh conclusion.
In simple terms, Cipla has won a procedural reprieve, not a final regulatory victory.
The fresh show-cause notice and the FDA's subsequent reasoned order will determine what happens next.
Disclaimer: This article is intended for informational purposes only and does not constitute investment advice. Investors should review official company disclosures, regulatory orders and market data before making investment decisions.
